Group 1 - The board of directors of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. held its 14th meeting of the 5th session on August 28, 2025, with 5 out of 6 directors present [1][2] - The meeting was chaired by Chairman Tang Yongqun and complied with relevant laws and regulations [1] - The board approved the half-year report for 2025 and its summary, which was previously reviewed by the audit committee [1][2] Group 2 - The board also approved a change in accounting policies, which was also reviewed by the audit committee prior to the meeting [2] - The voting results for both resolutions were unanimous, with 6 votes in favor and no votes against or abstaining [2]

Meeting Overview - The fourth meeting of the fourth board of directors of Dongni Electronics was held on August 29, 2025, in accordance with relevant laws and regulations [1][2] - All five directors attended the meeting, which was presided over by Mr. Shen Xiaoyu [1] Financial Report - The board approved the 2025 semi-annual report, which reflects the company's financial status as of June 30, 2025, and its operating results and cash flow for the first half of 2025 [2] - The audit committee confirmed that the financial information in the report fairly represents the company's financial condition [2] Asset Impairment - The board approved a proposal regarding the provision for asset impairment and asset write-offs for the first half of 2025, which will be submitted to the shareholders' meeting for approval [2][3] Shareholders' Meeting - A temporary shareholders' meeting is scheduled for September 15, 2025, at 14:00, to discuss the approved proposals [3][4]

Group 1 - The company held the 20th meeting of the 8th Board of Directors on August 29, 2025, with all 11 directors present, including participation via communication methods by some independent directors [1][2] - The meeting approved the 2025 semi-annual report and summary with unanimous consent, indicating a positive assessment of the company's financial status and operational results [1][2] - The Audit Committee reviewed and approved the semi-annual report, confirming compliance with regulations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange [2] Group 2 - The Board also approved the special report on the storage and actual use of raised funds for the first half of 2025, ensuring adherence to regulatory requirements for fundraising management [2]

Group 1 - The board of directors of Jomoo Holdings Co., Ltd. held its fourth meeting of the sixth session on August 26, 2025, in Xiamen, combining in-person and remote participation [1] - All nine directors attended the meeting, including independent director Mu Zhirong, who participated via video [1] - The meeting approved the full text and summary of the 2025 semi-annual report, which had been reviewed and agreed upon by the audit committee [1][2] Group 2 - The voting results showed 9 votes in favor, with no votes against or abstentions [2]

Core Viewpoint - The board of directors of Aili Home Technology Co., Ltd. held its 14th meeting of the third session, where they unanimously approved the 2025 semi-annual report and its summary, reflecting the company's financial status and operational results accurately [1][2]. Group 1: Board Meeting Details - The board meeting was held on August 27, 2025, with all 9 directors present, meeting the legal requirements for a valid resolution [1]. - The meeting was chaired by Chairman Song Zhengxing and conducted both in-person and via communication methods [1]. Group 2: Resolutions Passed - The board approved the proposal regarding the 2025 semi-annual report and its summary, which was deemed to fairly reflect the company's financial condition and operational results during the reporting period [1][2]. - The board also approved the special report on the storage and usage of raised funds for the first half of 2025, confirming that it adequately reflects the situation [2].

Core Points - The board of directors of Xiamen Songlin Technology Co., Ltd. confirmed that the content of the announcement is truthful, accurate, and complete, with no false records or misleading statements [1] - All board members attended the meeting, and all resolutions were passed unanimously with no dissenting votes [1][2] - The company’s 2025 semi-annual report and its summary were deemed compliant with relevant regulations and accurately reflect the company's financial status and operational results for the first half of 2025 [2][3] Financial Distribution - The profit distribution plan involves a cash dividend of 1.10 yuan (including tax) for every 10 shares, with no capital reserve fund conversion to share capital or bonus shares [2][3] - The profit distribution scheme aligns with the resolutions passed at the 2024 annual general meeting [3]

Meeting Overview - The third board meeting of Shaanxi Meibang Pharmaceutical Group Co., Ltd. was held on August 25, 2025, in Xi'an, Shaanxi Province, with all 9 directors present [1] - The meeting was convened in accordance with the Company Law of the People's Republic of China and the company's articles of association [1] Resolutions Passed - The board approved the 2025 semi-annual report and summary, which had previously been reviewed by the audit committee [2] - The board approved the special report on the storage and actual use of raised funds for the first half of 2025, also reviewed by the audit committee [2] - The board agreed to cancel the supervisory board and amend the articles of association, which will require shareholder approval [2][3] - The board passed resolutions to revise and abolish certain management systems, all requiring shareholder approval [3][4] - The board approved the convening of the first extraordinary general meeting of 2025 to be held on September 26, 2025 [5]

Meeting Overview - The sixth meeting of the board of directors of Tieliu Co., Ltd. was held on August 22, 2025, with all nine directors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The board approved the 2025 semi-annual report and its summary, with a unanimous vote of 9 in favor [2]. - The board approved the special report on the storage and actual use of raised funds for the first half of 2025, also with a unanimous vote of 9 in favor [2]. - The board approved a proposal regarding changes in accounting estimates, with a unanimous vote of 9 in favor [2]. - The board approved a proposal for the provision of asset impairment for the first half of 2025, with a unanimous vote of 9 in favor [2]. - The board elected Guo Ning as the representative director for company affairs, with a term lasting until the end of the current board's term, receiving a unanimous vote of 9 in favor [2]. - The board elected members for the audit committee, including Yang Qing, Zhang Zhiling, and Zhang Tong, with a unanimous vote of 9 in favor [3].

Group 1 - The board of directors of Hubei Junyao Health Beverage Co., Ltd. held its 16th meeting of the 5th session on August 22, 2025, with all 9 directors present, complying with relevant regulations [1][2] - The board approved the 2025 semi-annual report and its summary, with a unanimous vote of 9 in favor [2] - The board also approved a special report on the storage and actual use of raised funds for the first half of 2025, again with a unanimous vote of 9 in favor [2]

Group 1 - The board of directors of Demar Technology Group Co., Ltd. held its 25th meeting on August 25, 2025, with all 9 directors present, ensuring compliance with relevant laws and regulations [1] - The board approved the 2025 semi-annual report and its summary, confirming that the report's preparation and review procedures were legal and compliant with regulations [2] - The board also approved a special report on the use of raised funds for the first half of 2025, with all votes in favor [2] Group 2 - The board approved a proposal to amend the company's articles of association, which will require further approval from the shareholders' meeting [3] - A resolution was passed to invalidate a portion of the restricted stock incentive plan from 2022, as the performance targets for 2024 were not met, resulting in the cancellation of 685,000 shares [3][4] - The board approved a proposal to convene the first temporary shareholders' meeting of 2025, with unanimous support from the directors [5]